2 reports of this reaction
4.2% of all AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 2 FDA adverse event reports linking AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE to FATIGUE. This represents approximately 4.2% of all 48 adverse event reports for this drug.
Patients taking AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2 FDA reports for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.2% of all adverse event reports for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, making it a notable side effect.
If you experience fatigue while taking AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.